Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Mutation order influences cancer outcome

16 February 2015

By Dr Nicoletta Charolidi

Appeared in BioNews 790

The order in which mutations occur in a cell can determine the clinical outcome of certain cancers, according to research published in the New England Journal of Medicine.

The researchers isolated and examined individual, healthy and cancerous stem cells from the blood of patients with myeloproliferative neoplasms (MPNs) - a group of pre-leukemic disorders.

By identical or 'clonal' expansion of each of the isolated cells, the researchers were able to study the evolution of mutations seen in these conditions, which often concern two genes called JAK2 and TET2.

They reported that patients in whom the JAK2 gene was mutated before the TET2 gene were more likely to have a worse disease course, suffering blood clots and other symptoms, over a decade earlier than those who had a mutation in the TET2 gene first. However, the JAK2-first affected patients were more responsive to available anti-JAK2 drugs.

Dr David Kent, one of the study authors, from the University of Cambridge, said: 'This surprising finding could help us offer more accurate prognoses to MPN patients based on their mutation order and tailor potential therapies towards them. For example, our results predict that targeted JAK2 therapy would be more effective in patients with one mutation order but not the other.'

MPNs are characterised by a functionally impaired bone marrow, the tissue responsible for blood production. The result is over-accumulation of blood cells which increase the risk of blood clots and leukaemia. MPNs are often early identified through routine blood tests and are generally treatable, as they represent an earliest stage of cancer. The researchers, however, suggest that the findings may apply to solid tumours too.

Professor Antony Green, who led the study, noted: 'This is the first time that mutation order has been shown to affect any cancer, and it is likely that this phenomenon occurs in many types of malignancy.'

'These results show how study of the MPNs provides unparalleled access to the earliest stages of tumour development (inaccessible in other cancers, which usually cannot be detected until many mutations have accumulated). This should give us powerful insights into the origins of cancer.'

SOURCES & REFERENCES
New England Journal of Medicine | 12 February 2015
 
Scientific American | 11 February 2015
 
University of Cambridge (press release) | 11 February 2015
 
Cancer Research UK | 11 February 2015
 
Medscape | 11 February 2015
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

15 June 2015 - by Hannah Somers 
Two US studies have identified specific genetic mutations in gliomas which correlate with how the tumours will behave and respond to treatment...
02 March 2015 - by Dr Linda Wijlaars 
This well-timed Panorama documentary details how innovative treatments are being developed at the Institute of Cancer Research and trialled at the Royal Marsden...

16 December 2013 - by Dr Rachel Brown 
Gene therapy trials using engineered immune cells have shown considerable progress in treating blood disorders, according to findings presented at the American Society of Hematology's annual meeting...
07 May 2013 - by Suzanne Elvidge 
Genetic analysis of tumours provides the key to treating them effectively, according to two studies carried out by The Cancer Genome Atlas (TCGA)....
05 December 2011 - by Dr Zara Mahmoud 
Two new gene variants, which each increase the risk of bone marrow cancer by 30 percent, have been identified by scientists at the Institute for Cancer Research...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation